Business
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n\n - Announces Series C Preferred Stock Offering \n - Updates Status of Clinical Pipeline in Central Nervous System Disorders  LOS ANGELES, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) --  - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a clinical-stage developer of non-invasive electroceutical devices for the treatment of central nervous system (CNS) disorders, has provided a corporate update and outlook for 2018. Plans to Complete Clinical Trial to Study Effects of tPEMF in Patients with Brain Injury Endonovo plans to complete a single center, prospective, controlled, clinical trial of tPEMF to evaluate the effects of tPEMF in patients with brain injury and external ventricular drain (EVD) in an intensive care unit (ICU) setting. This clinical study is an extension of a safety trial and will be open to all patients who have or are fitted with an external ventricular drain (EVD) to remove excess cerebrospinal fluid (CSF). Redesign tPEMF Products for Use in Central Nervous System Disorders Endonovo plans to redesign tPEMF products for use in CNS disorders in order to make its tPEMF therapy easier to use and increase patient compliance. Endonovo believes that industrial design and engineering of non-invasive electroceutical devices will be a critical component to the precise stimulation of areas in the CNS that require treatment and allow patients to use the therapy in an in-home setting. Initiate Previously Planned Studies of tPEMF in Post-Concussion Syndrome and Acute Concussions Endonovo plans to initiate previously planned clinical trials to study the effects of tPEMF in patients with Post-Concussion Syndrome (PCS) and Acute Sports-related Concussions upon the redesign of its tPEMF devices for use in CNS disorders. Initiate Previously Planned Feasibility Study for Use of tPEMF In Patients with Multiple Sclerosis Endonovo plans to initiate an open-label study of tPEMF treatment in patients with multiple sclerosis (MS) that will be used to assess feasibility and tolerability of tPEMF therapy and to generate preliminary data on clinically relevant outcomes. Pursuing Licensing, Distribution, and Partnership Opportunities for FDA-Cleared Devices Endonovo plans to commercialize its CE-Marked and FDA-Cleared Electroceutical™ therapy in China, Japan, Korea and other international ...